Lithuania will be joining the European Molecular Biology Labaratory (EMBL) as a full member state. This will enable Lithuanian experts in biotechnology and biopharmaceuticals to more actively seek new scientific discoveries and develop innovations needed for the market.
The EMBL Board voted to welcome Lithuania to the organization on July 4th.
“With Lithuania’s involvement in international research infrastructure, the opportunities open up for our science to get acquainted with the latest achievements, to work with state of art laboratory equipment, to be at the doorsteps of new discoveries. It is important that Lithuanian biotechnologists will join the European molecular biology elite club as equal members”, – says Jurgita Petrauskienė, Lithuanian Minister of Education and Science.
The European Laboratory for Molecular Biology is the world’s leading laboratory research center for life sciences, which provide access to the most advanced laboratory equipment. Member states receive access to all EMBL’s facilities and services, they also participate in decision making about the organization. EMBL has 20 member states.
Modern life sciences are very dynamic, experimental research methods and technologies are developing very quickly, so national research infrastructures need to have access to state of the art scientific technology and equipment in order to remain competitive. Lithuanian scientists and doctoral students will have the opportunity to conduct research in EMBL centers in Germany, Spain, France, the United Kingdom and Italy. EMBL research teams can be set up in Lithuania, attracting top scientists from the world.
The Lithuanian biotechnology and biopharmaceutical sector is considered to be one of the most successful and promising in the world, both in the highest level of research and in successfully operating businesses.
Biotechnology in Lithuania creates about 1% of the GDP, that is around 10 times more than in any other EU member state on average. Lithuania’s life sciences sector exports to almost 70 countries, it grows by 19% annually. It is expected that the sector will create around 1.5% of GDP employing only 0.1 of total employees in 2019.
The production of Thermo Fisher Scientific, Sicor Biotech and Biotechpharma, the leading Lithuanian companies in biotech sector, amounted to 396 million Euro in 2016, their growth is around 25% every year.
Lithuania has a particularly high scientific potential in the field of molecular technology. Molecular technology and medical engineering in Lithuania hold the first place in the number of scientific and business patents, the number of citations of Lithuanian molecular technology research works is higher than the average world. Health technologies and biotechnology are one of the most advanced areas of intelligent specialization in Lithuania.
This year, Lithuania has already joined two world-class scientific centers: European Organization for Nuclear Research (CERN). Lithuania is also on its way to the membership of the European Laser Center (ELI).
Information prepared according the press release of the Ministry of Education and Science.